Method and kit for screening early-stage ovarian cancer

A technology of ovarian cancer and a kit, which is applied in the field of tumor screening, can solve the problems of false positives, low specificity and sensitivity, and little significance for early auxiliary diagnosis of ovarian cancer, so as to achieve the effect of improving accuracy

Active Publication Date: 2018-03-06
华明康生物科技(深圳)有限公司
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

CA125 is a commonly used tumor marker, but the specificity and sensitivity of CA125 are low, and it is prone to false negative or false positive
Compared with CA125, HE4 has higher sensitivity and stronger specificity, but it is still of little significance for the early auxiliary diagnosis of ovarian cancer. The sensitivity of a single HE4 for auxiliary diagnosis of stage I ovarian cancer is only 45.9%.
Simultaneous detection of two biomarkers can improve detection sensitivity, but the false positive rate is high, and early auxiliary diagnosis is still not possible
Neither CA125 nor HE4 accurately predicts early ovarian cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and kit for screening early-stage ovarian cancer
  • Method and kit for screening early-stage ovarian cancer
  • Method and kit for screening early-stage ovarian cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] The present invention will be described in detail below in conjunction with the accompanying drawings and embodiments.

[0021] The invention provides the use of cutinase protein (YKL-40) in combination with cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) in early ovarian cancer screening.

[0022] CA125 is a glycoprotein derived from columnar epithelial cells. In 1983, Bast et al. first measured the content of serum CA125, and then researchers analyzed the level of CA125 in ovarian cancer patients to determine the role of this molecule in the auxiliary diagnosis of ovarian cancer. CA125 is currently the main serum marker for screening early ovarian cancer. It has been widely used in clinical auxiliary diagnosis, curative effect observation and disease monitoring, but its sensitivity is low when used alone for auxiliary diagnosis of early ovarian cancer. In early ovarian cancer, only some stage I patients have serum CA125 elevation (>35U / ml), and physiol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The present invention discloses a method and kit for screening early-stage ovarian cancer. According to the method, early-stage ovarian cancer is screened through combined detection of keratanase protein (YKL-40), cancer antigen 125 (CA125) and human epididymis protein 4 (HE4). With the method, the early-stage ovarian cancer prediction accuracy can be improved.

Description

technical field [0001] The invention relates to the technical field of tumor screening, in particular to an early ovarian cancer screening method and a kit. Background technique [0002] Ovarian cancer is one of the common malignant tumors of female reproductive organs. Its incidence rate ranks third among all kinds of gynecological cancers in women, but its mortality rate ranks first, posing a serious threat to women's life and health. Due to the complexity of embryonic development, tissue anatomy and endocrine function of the ovary, its pathogenesis has not yet been studied clearly. And because there are no obvious symptoms in the early clinical stage of ovarian cancer, most patients are already in the advanced stage when they are discovered, and can only receive conservative treatment. Some research reports suggest that only 30% of ovarian cancer tumors are found to be confined to the ovary during exploratory laparotomy, and most of them have spread to the bilateral appe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/574
CPCG01N33/57449G01N33/57473G01N33/57484G01N33/6803
Inventor 何传华李作生王岳鹏李大伟王朝阳仇家舟何浩然
Owner 华明康生物科技(深圳)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap